Cilengitide in Subjects With Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). [The CORE Study]
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Cilengitide (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms CORE
- Sponsors Merck KGaA
- 19 Jan 2016 Pooled analysis of 4 studies (n=1869) including data from this study and 3 other trials (see CTP 700046838, 700038467, 700034867) were published in the Journal of Clinical Oncology.
- 24 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Oct 2012 Planned end date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.